Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia

Br J Haematol. 2022 Aug;198(4):780-784. doi: 10.1111/bjh.18290. Epub 2022 May 26.

Authors

Alexis Genthon¹, Diana Dragoi¹, Mara Memoli¹, Pierre Hirsch², Fabrizia Favale², Ludovic Suner², Michael Chaquin², Pierre Boncoeur², Zora Marjanovic¹, Agnès Bonnin¹, Simona Sestili¹, Remy Dulery¹, Florent Malard¹, Eolia Brissot¹, Anne Banet¹, Zoe van de Wyngaert¹, Anne Vekhoff¹, Francois Delhommeau², Mohamad Mohty¹, Ollivier Legrand¹

Affiliations

¹ Service d'hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, INSERM UMRs 938, Sorbonne Université, Paris, France.
² Service d'Hématologie Biologique, Hôpital Saint Antoine, AP-HP, Centre de Recherche Saint-Antoine (CRSA), INSERM UMR938, Sorbonne Université, Paris, France.

PMID: 35615877
DOI: 10.1111/bjh.18290

No abstract available

Keywords: AML; IDH; allo-SCT; enasidenib; ivosidenib.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Enzyme Inhibitors / pharmacology
Hematopoietic Stem Cell Transplantation*
Humans
Isocitrate Dehydrogenase / genetics
Leukemia, Myeloid, Acute* / therapy

Substances

Enzyme Inhibitors
Isocitrate Dehydrogenase